PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme
- PMID: 7583554
- DOI: 10.1161/01.atv.15.10.1764
PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme
Abstract
In human plasma, platelet activating factor (PAF)-degrading acetylhydrolase (acetylhydrolase) is principally transported in association with LDLs and HDLs; this enzyme hydrolyzes PAF and short-chain forms of oxidized phosphatidylcholine, transforming them into lyso-PAF and lysophosphatidylcholine, respectively. We have examined the distribution, catalytic characteristics, and transfer of acetylhydrolase activity among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation; the possibility that the plasma enzyme may be partially derived from adherent monocytes has also been evaluated. In normolipidemic subjects with Lp(a) levels < 0.1 mg/mL, acetylhydrolase was associated preferentially with small, dense LDL particles (LDL-5; d = 1.050 to 1.063 g/mL) and with the very-high-density lipoprotein-1 subfraction (VHDL-1; d = 1.156 to 1.179 g/mL), representing 23.9 +/- 1.7% and 20.6 +/- 3.2%, respectively, of total plasma activity. The apparent Km values for PAF of the enzyme associated with such lipoproteins were 89.7 +/- 23.4 and 34.8 +/- 4.5 mumol/L for LDL-5 and VHDL-1, respectively: indeed, the Km value for LDL-5 was some 10-fold higher than that of the light LDL-1, LDL-2, and LDL-3 subspecies, whereas the Km of VHDL-1 was some twofold greater than those of the HDL-2 and HDL-3 subspecies. Furthermore, when expressed on the basis of unit plasma volume, the Vmax of the acetylhydrolase associated with LDL-5 was some 150-fold greater than that in LDL-1 (d = 1.019 to 1.023 g/mL). No significant differences in the pH dependence of enzyme activity or in sensitivity to protease inactivation, sulfydryl reagents, the serine protease inhibitor Pefabloc, or the PAF antagonist CV 3988 could be detected between apo B-containing and apo A-I-containing lipoprotein particle subspecies. Incubation of LDL-1 (Km = 8.4 +/- 2.6 mumol/L) and LDL-2 (d = 1.023 to 1.029 g/mL; Km = 8.4 +/- 3.3 mumol/L) subspecies with LDL-5, in which acetylhydrolase had been inactivated by pretreatment with Pefabloc, demonstrated preferential transfer of acetylhydrolase to LDL-5. Acetylhydrolase transferred to LDL-5 from the light LDL subspecies exhibited a Km of 9.4 +/- 2.2 mumol/L, a value characteristic of the particle donors. Finally, acetylhydrolase (Km = 23.4 +/- 7.6 mumol/L) released by adherent human monocytes in culture was found to bind preferentially to small, dense LDL subspecies upon incubation of Pefabloc-inactivated plasma with monocyte supernatant.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.Atherosclerosis. 1996 Aug 23;125(1):121-34. doi: 10.1016/0021-9150(96)05872-8. Atherosclerosis. 1996. PMID: 8831934
-
Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.Biochim Biophys Acta. 1999 Jan 29;1437(1):23-36. doi: 10.1016/s0005-2760(98)00177-5. Biochim Biophys Acta. 1999. PMID: 9931415
-
Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).Arterioscler Thromb. 1993 Jul;13(7):1066-75. doi: 10.1161/01.atv.13.7.1066. Arterioscler Thromb. 1993. PMID: 8318508
-
The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.Biochim Biophys Acta. 2009 May;1791(5):327-38. doi: 10.1016/j.bbalip.2009.02.015. Biochim Biophys Acta. 2009. PMID: 19272461 Review.
-
Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure.Pharmaceuticals (Basel). 2010 Mar 8;3(3):541-557. doi: 10.3390/ph3030541. Pharmaceuticals (Basel). 2010. PMID: 27713267 Free PMC article. Review.
Cited by
-
Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.BBA Clin. 2017 Aug 19;8:66-77. doi: 10.1016/j.bbacli.2017.07.002. eCollection 2017 Dec. BBA Clin. 2017. PMID: 28936395 Free PMC article. Review.
-
Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.PLoS Genet. 2010 Apr 29;6(4):e1000928. doi: 10.1371/journal.pgen.1000928. PLoS Genet. 2010. PMID: 20442857 Free PMC article.
-
Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?Curr Cardiol Rev. 2020;16(1):3-10. doi: 10.2174/1573403X15666190531111932. Curr Cardiol Rev. 2020. PMID: 31146670 Free PMC article. Review.
-
Why targeting HDL should work as a therapeutic tool, but has not.J Cardiovasc Pharmacol. 2013 Sep;62(3):239-46. doi: 10.1097/FJC.0b013e31829d48a5. J Cardiovasc Pharmacol. 2013. PMID: 23743767 Free PMC article. Review.
-
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.Arthritis Res Ther. 2007;9(1):R19. doi: 10.1186/ar2129. Arthritis Res Ther. 2007. PMID: 17326817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous